Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

02/14/2018 | 10:57am EDT
A trader passes by a screen displaying the tickers symbols for Bristol-Myers Squibb on the floor at the New York Stock Exchange

(Reuters) - Bristol-Myers Squibb Co (>> Bristol-Myers Squibb Company) will pay Nektar Therapeutics (>> Nektar Therapeutics) $1.85 billion(1.33 billion pounds) for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

(Reuters) - Bristol-Myers Squibb Co (>> Bristol-Myers Squibb Company) will pay Nektar Therapeutics (>> Nektar Therapeutics) $1.85 billion(1.33 billion pounds) for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

In one of the largest single-drug collaboration deals ever, Nektar will receive $1 billion in cash upfront and Bristol-Myers will purchase about 8.28 million Nektar shares at $102.60 per share, or an equity stake of just under 5 percent of the company. Nektar shares closed at $75.66 on Tuesday.

If all potential development, regulatory and sales milestones in the deal are met, it could be worth more than $3.6 billion to Nektar, while giving Bristol-Myers a new immunotherapy platform.

Nektar shares were up 8 percent at $81.74, while Bristol-Myers shares rose 0.7 percent to $64.32.

"We believe the deal economics are favorable to both parties," Cowen analyst Chris Shibutani said in a research note.

The partnership is built around the Nektar drug, NKTR-214, which will be tested with Bristol's immuno-oncology (IO) drugs Opdivo and Opdivo and Yervoy in 20 cancer indications across nine different tumor types, including melanoma, kidney and lung cancers, following "very encouraging" early data from clinical trials.

"We've been in a clinical collaboration with Nektar since 2016. This partnership was a natural next step," Paul Biondi, head of business development for Bristol-Myers, said in a telephone interview.

The combination therapies could become "potentially a new backbone in the IO space," he added.

The announcement comes as early immunotherapy leader Bristol-Myers has been viewed by investors as having fallen behind Merck & Co (>> Merck and Company) in the burgeoning field, especially in the most lucrative lung cancer space.

NKTR-214, a CD122 agonist that utilizes the interleukin-2 (IL-2) pathway, is designed to increase the number and activation state of cancer-fighting T cells in the tumor microenvironment, while limiting IL-2 toxicity, with the hope of improving and lengthening patient responses.

Nektar is also eligible to receive an additional $1.78 billion in milestone payments, of which $1.43 billion are development and regulatory milestones and the remainder are sales milestones.

Following approvals, Nektar will book revenue for worldwide NKTR-214 sales and the companies will split global profits, with Nektar receiving 65 percent and Bristol-Myers 35 percent, they said. Bristol-Myers will retain 100 percent of revenues for its own medicines.

The transaction is expected to be completed in the second quarter of 2018, the companies said.

Both companies would be free to develop NKTR-214 with other drugs for uses not laid out in the deal.

(Reporting by Bill Berkrot; Editing by Rosalba O'Brien and Jonathan Oatis)

By Bill Berkrot


ę Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.30% 67.49 Delayed Quote.8.80%
HOPE, INC. -0.29% 697 End-of-day quote.-84.49%
MERCK & CO., INC. 0.79% 77.85 Delayed Quote.-4.83%
SPACE CO.,LTD. 1.98% 929 End-of-day quote.17.74%
STEP CO.,LTD. -0.28% 1810 End-of-day quote.13.34%
All news about BRISTOL-MYERS SQUIBB COMPANY
07/27BRIDGEBIO PHARMA : Bristol Myers Squibb to Evaluate BBP-398 Combined With Opdivo..
MT
07/23BRISTOL MYERS SQUIBB : Statement on Opdivo« (nivolumab) Monotherapy Post-Sorafen..
PU
07/19PORTAGE BIOTECH CEO INTERVIEW EXPLAI : Prtg)
AQ
07/19COMPUGEN : Doses First Patient in Expansion Arm of Study Evaluating Triple Combi..
MT
07/19BRISTOL MYERS SQUIBB : MPN Hub continues to enhance global knowledge of myelopro..
AQ
07/19AML Hub continues to enhance global knowledge of acute myeloid leukemia throu..
AQ
07/16BRISTOL MYERS SQUIBB : Says Study of Opdivo Plus Yervoy Against Carcinoma Did No..
MT
07/16Bristol Myers Squibb Cancer Drug Study Falls Short of Endpoints
DJ
07/16BRISTOL MYERS SQUIBB : Provides Update on CheckMate -651 Trial Evaluating Opdivo..
BU
07/16Bristol-Myers Squibb Company Provides Update on Checkmate -651 Trial Evaluati..
CI
More news
Financials (USD)
Sales 2021 46 031 M - -
Net income 2021 7 797 M - -
Net Debt 2021 28 265 M - -
P/E ratio 2021 19,8x
Yield 2021 2,88%
Capitalization 151 B 151 B -
EV / Sales 2021 3,89x
EV / Sales 2022 3,47x
Nbr of Employees 30 250
Free-Float 76,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 67,49 $
Average target price 75,18 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY8.80%150 695
JOHNSON & JOHNSON9.71%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.14.37%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.27%221 084